Clinical Trial

Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated October 2024 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to: 1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2. Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy. 3. Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.
Trial Details
NCT Number NCT06546059
Lead Sponsor South Valley University
Conditions Vitiligo, Generalized
Enrollment 40 participants
Start Date 2024-08
Primary Completion 2024-10 (estimated)
Study Completion 2024-11 (estimated)
Updated on ClinicalTrials.gov 2024-08-09